The payment processing landscape for vapor retailers may be shifting once again. 

After weeks of concern from retailers, distributors, and convenience store operators, Mastercard has announced it is temporarily pausing assessments related to Electronic Nicotine Delivery System (ENDS) products while it reevaluates its compliance approach. The decision comes in response to a letter from the National Association of Convenience Stores (NACS), which argued that the company's enforcement efforts did not align with the FDA's current regulatory framework. 

For businesses that have been navigating conflicting compliance expectations, the announcement represents an important development—but it doesn't eliminate the uncertainty. 

Why the Issue Began 

Earlier this summer, retailers across the United States began receiving warnings from payment processors and merchant service providers indicating they could face significant financial penalties—or even lose payment processing privileges—for selling any vaping products that were not specifically authorized by the FDA. 

The concern stemmed from the fact that the FDA has issued marketing granted orders for only 45 ENDS products, despite thousands of products remaining on the market under various stages of regulatory review or FDA enforcement discretion. 

Retailers quickly found themselves caught between two different interpretations of federal policy: 

• FDA enforcement priorities  

• Payment network compliance policies  

While FDA authorization remains legally required under the Tobacco Control Act, the agency has historically exercised enforcement discretion rather than removing every unauthorized product from commerce immediately. 

NACS Challenges Mastercard's Interpretation 

In response, NACS—along with several industry organizations—sent a formal letter to Mastercard requesting clarification. 

Their central argument was straightforward: 

Although FDA premarket authorization is required, the agency does not currently treat every unauthorized product as an enforcement priority. 

Following updated FDA guidance released in May, NACS argued that payment networks were effectively creating a stricter compliance standard than the federal regulator itself. 

For retailers, that meant facing potential penalties even when products were not currently the subject of FDA enforcement action. 

Mastercard Responds 

On July 27, Mastercard responded by announcing that it would temporarily pause assessments while additional information is reviewed. 

According to Mastercard: 

"Mastercard's compliance programs are designed to ensure adherence to applicable laws and our network standards... we have decided to temporarily pause any assessments to provide customers additional time to execute their remediation plans and ensure compliance." 

While the company did not announce a permanent policy change, the decision signals a willingness to reconsider how its compliance standards are being applied. 

Why This Matters for Retailers 

For many businesses, this announcement provides temporary breathing room. 

Retailers had been facing reports of potential penalties reaching hundreds of thousands of dollars for alleged violations involving products that, while unauthorized, were not necessarily being targeted by FDA enforcement. 

Major companies—including BP, Marathon Petroleum, Valero, and payment platform Fiserv—had previously warned merchants about possible fines and payment processing consequences tied to unauthorized ENDS products. 

Those notices created widespread confusion throughout the industry, particularly among retailers attempting to follow existing federal guidance while also maintaining payment processing services. 

The Regulatory Landscape Remains Complicated 

Despite Mastercard's pause, the broader regulatory environment has not become any simpler. 

Several state attorneys general continue to pressure payment processors, shipping companies, and online marketplaces to restrict transactions involving what they characterize as illegal vaping products. 

At the same time, FDA has authorized only 45 vaping products through the Premarket Tobacco Product Application (PMTA) process, leaving the vast majority of products operating within an increasingly complex regulatory framework. 

As a result, retailers continue to navigate multiple layers of oversight: 

• FDA regulations  

• State enforcement initiatives  

• Payment processor policies  

• Card network compliance requirements  

Each may apply different standards or enforcement priorities. 

What Retailers Should Do Next 

Although Mastercard has paused assessments, businesses should view the announcement as an opportunity—not a resolution. 

Retailers should continue to: 

• Review their current product inventory.  

• Maintain documentation from suppliers regarding regulatory status.  

• Monitor communications from payment processors and merchant service providers.  

• Stay informed about evolving FDA guidance and network policy updates.  

Until Mastercard announces its final position, merchants should remain prepared for additional compliance requirements while avoiding unnecessary disruption to their operations. 

A Positive Step Toward Regulatory Alignment 

Mastercard's decision to temporarily pause assessments suggests that industry concerns are being heard. 

For retailers, distributors, and manufacturers, the hope is that future payment network policies will better reflect the FDA's actual enforcement priorities rather than creating a separate compliance standard that adds confusion for businesses already operating in one of the country's most heavily regulated industries. 

While questions remain, this development represents an encouraging step toward greater consistency between regulatory expectations and private-sector enforcement—something the vapor industry has long advocated for.